

Please add the following new claims:

Sub C1
B
~~45. (New) A method for ameliorating the effects of a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation with an effective amount of a nucleic acid molecule selected from the group consisting of 5'-ATCTCTCCGCTTCTTTC-3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules wherein said nucleic acid molecule or its chemical analogue is capable of inhibiting or otherwise reducing growth factor mediated cell proliferation and/or inflammation and/or other medical disorders.~~

Sub D1
46. (New) A method according to Claim 45 wherein the mammal is a human.

47. (New) A method according to Claim 45 wherein cell proliferation and/or inflammation is mediated by at least one of insulin-like growth factor I (IGF-I), keratinocyte growth factor (KGF), transforming growth factor- α (TGF α), tumour necrosis factor- α (TNF α), interleukin (IL) -1 (IL-1), IL-4, IL-6, IL-8 and/or basic fibroblast growth factor (bFGF).

48. (New) A method according to Claim 47 wherein cell proliferation and/or inflammation is mediated by IGF-I.

Sub D2
49. (New) A method according to Claim 45 wherein the proliferative or inflammatory skin disorder is psoriasis, eczema, ichthyosis, pityriasis, rubra, pilaris, seborrhoea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.

B'
50. (New) A method according to Claim 49 wherein the skin condition is psoriasis.

51. (New) A method according to Claim 45 herein the nucleic acid molecule is 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10) or chemical analogue thereof.

52. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or chemical analogue thereof.

53. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) or chemical analogue thereof.

54. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUC-3' (SEQ ID NO:14) or chemical analogue thereof.

55. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15) or chemical analogue thereof.

56. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) or chemical analogue thereof.

57. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) or chemical analogue thereof.

58. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or chemical analogue thereof.

59. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) or chemical analogue thereof.

60. (New) A method according to Claim 45 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue thereof.

61. (New) A nucleic acid molecule comprising at least about 15 nucleotides capable of hybridizing to or forming a heteroduplex or otherwise interacting with a complementary form of SEQ ID NO:10 or SEQ ID NO:12 to SEQ ID NO:20 inclusive.

62. (New) A nucleic acid molecule comprising at least about 15 nucleotides capable of hybridizing to or forming a heteroduplex or otherwise interacting with a complementary form of SEQ ID NO:12 to SEQ ID NO:20 inclusive.

~~63.~~ (New) A nucleic acid molecule comprising at least about 15 nucleotides capable of hybridizing to or forming a heteroduplex or otherwise interacting with a complementary form of SEQ ID NO:12 to SEQ ID NO:14 or SEQ ID NO:20 inclusive.

B1
SUB C2 } ~~64.~~ (New) A method of ameliorating the effects of psoriasis in a mammal, said method comprising contacting proliferating skin or skin capable of proliferation with an effective amount of one or more nucleic acid molecules or chemical analogues thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation wherein said one or more molecules comprises a polynucleotide selected from the group consisting of 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules which is capable of interacting with mRNA directed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an IGFBP.

Sub IDB } 65. (New) A method according to Claim 64 wherein the mammal is a human.

66. (New) A method according to Claim 64 herein the nucleic acid molecule is 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10) or chemical analogue thereof.

67. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or chemical analogue thereof.

68. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) or chemical analogue thereof.

69. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14) or chemical analogue thereof.

70. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15) or chemical analogue thereof.

71. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) or chemical analogue thereof.

72. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) or chemical analogue thereof.

73. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or chemical analogue thereof.

74. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) or chemical analogue thereof.

D3
con
75. (New) A method according to Claim 64 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue thereof.

SUB C3
B1
~~76. (New) A composition comprising a nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation, said composition comprising a nucleic acid molecule selected from the group consisting of 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.~~

Sub D3
77. (New) A composition according to Claim 76 wherein the mammal is a human.

78. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10) or chemical analogue thereof.

Sub D4
79. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or chemical analogue thereof.

Del
80. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) or chemical analogue thereof.

81. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14) or chemical analogue thereof.

Sub 005
82. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15) or chemical analogue thereof.

83. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) or chemical analogue thereof.

B
84. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) or chemical analogue thereof.

Sub 47
A method according to Claim 73 or 74 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or chemical analogue thereof.

Sub 05
85. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) or chemical analogue thereof.

86. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue thereof.

Sub 05
87. (New) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue thereof.